Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

ICU

SeaStar Medical Holding Corp

Nov 19 • 04:00PM ET

0.3112

-0.0239 -7.13 %

Healthcare • Biotechnology • USA • NASD

Peers: ISRG ABT MDT SYK BSX BAX RMD EW TFX HOLX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.49	Insider Own	1.04%	Shs Outstand	36.05M	Perf Week	-37.67%
Market Cap	11.22M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	41.24%	Shs Float	35.67M	Perf Month	-50.60%
Enterprise Value	-2.54M	PEG	-	EPS next Q	-0.11	Inst Own	3.03%	Short Float	1.73%	Perf Quarter	-61.10%
Income	-13.66M	P/S	12.75	EPS this Y	90.50%	Inst Trans	-2.49%	Short Ratio	0.31	Perf Half Y	-76.06%
Sales	0.88M	P/B	0.93	EPS next Y	30.16%	ROA	-135.86%	Short Interest	0.62M	Perf YTD	-83.96%
Book/sh	0.34	P/C	0.82	EPS next 5Y	63.22%	ROE	-290.37%	52W High	3.07 -89.86%	Perf Year	-85.79%
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	9.03% -407.48%	ROIC	-119.20%	52W Low	0.30 3.35%	Perf 3Y	-99.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	17.15% 11.21%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-2.89	EPS Y/Y TTM	87.66%	Oper. Margin	-1580.48%	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.64	Sales Y/Y TTM	1195.59%	Profit Margin	-1551.08%	RSI (14)	26.90	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.66	EPS Q/Q	87.99%	SMA20	-37.15%	Beta	-0.88	Target Price	1.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	169.12%	SMA50	-51.06%	Rel Volume	0.40	Prev Close	0.34
Employees	19	LT Debt/Eq	0.00	Earnings	Nov 13 AMC	SMA200	-70.70%	Avg Volume	1.98M	Price	0.31
IPO	Mar 18, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	13.33% -26.80%	Trades		Volume	790,030	Change	-7.13%

Nov-17-25 08:43AM	SeaStar Medical Announces Appointment of Michael Messinger as CFO (GlobeNewswire) -20.26%
Nov-14-25 12:04AM	SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -17.39%
Nov-13-25 04:05PM	SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.85%
Nov-05-25 10:03AM	SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025 (GlobeNewswire)
Sep-29-25 08:36AM	SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children (GlobeNewswire)
04:22PM	Loading…
Sep-24-25 04:22PM	SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury (GlobeNewswire) +6.90% -50.94%
Sep-23-25 08:23AM	SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children (GlobeNewswire) +16.00%
Sep-04-25 06:13PM	SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference (GlobeNewswire) -5.21%
Sep-02-25 08:22AM	SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival (GlobeNewswire)
Aug-14-25 03:14AM	SeaStar Medical Holding Corp (ICU) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.98%
Aug-13-25 04:05PM	SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-07-25 10:00AM	SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025 (GlobeNewswire)
Aug-06-25 08:33AM	SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI) (GlobeNewswire) +7.03%
Jul-31-25 03:01PM	SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.37%
Jul-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +12.53%
08:20AM	Loading…
08:20AM	SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients (GlobeNewswire)
Jul-16-25 08:45AM	SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry (GlobeNewswire) +9.18%
Jul-10-25 03:29PM	SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.15%
Jul-08-25 08:05AM	SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI) (GlobeNewswire) +47.62%
Jul-02-25 04:25PM	SeaStar Medical Announces Positive Nasdaq Listing Determination (GlobeNewswire) +15.46%
Jun-25-25 08:05AM	SeaStar Medical Reports Update on Nasdaq Listing Status (GlobeNewswire) +17.63%
Jun-24-25 09:05AM	SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy (GlobeNewswire) +8.35%
Jun-20-25 12:10PM	SeaStar Medical Announces Pricing of Up to $8 Million Public Offering (GlobeNewswire) -63.89%
Jun-11-25 08:25AM	AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research (GlobeNewswire)
May-29-25 10:13AM	SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market (NewMediaWire)
May-28-25 08:05AM	SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy (GlobeNewswire)
May-14-25 04:05PM	SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-13-25 08:05AM	SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (GlobeNewswire)
May-07-25 10:00AM	SeaStar Medical to Report First Quarter Financial Results on May 14, 2025 (GlobeNewswire)
Apr-30-25 08:05AM	SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time (GlobeNewswire)
08:05AM	Loading…
Apr-08-25 08:05AM	FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery (GlobeNewswire) -6.72%
Mar-27-25 04:05PM	SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) -9.47% -22.73%
Mar-24-25 05:30PM	SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 (GlobeNewswire)
Mar-18-25 08:45AM	NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award (PR Newswire)
Feb-03-25 04:05PM	SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) -16.23%
Jan-31-25 08:00AM	SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) +29.48%
Jan-27-25 08:00AM	SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE (GlobeNewswire)
Jan-22-25 07:30AM	SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial (GlobeNewswire) -5.71%
Jan-14-25 08:35AM	SeaStar Medical says FDA approves feasibility study with SCD-ADULT (TipRanks)
Jan-13-25 08:30AM	FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome (GlobeNewswire)
Jan-08-25 08:30AM	SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer (GlobeNewswire)
Dec-23-24 07:00AM	SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial (GlobeNewswire)
Dec-11-24 06:30AM	SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications (GlobeNewswire) -7.11%
Dec-04-24 08:30AM	SeaStar Medical to Hold Business Update Conference Call on December 11, 2024 (GlobeNewswire) +7.17%
Dec-03-24 08:30AM	SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial (GlobeNewswire)
Nov-26-24 08:00AM	SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024 (GlobeNewswire) +7.98%
Nov-22-24 08:30AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares (GlobeNewswire) -6.82%
Nov-15-24 08:30AM	SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer (GlobeNewswire) +11.73%
Nov-13-24 05:05PM	SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -5.62% -22.22%
Nov-06-24 09:00AM	FDA Grants Breakthrough Device Designation for SeaStar Medical's Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis (GlobeNewswire)
Nov-01-24 08:30AM	Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial (GlobeNewswire)
Oct-31-24 08:30AM	SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE (GlobeNewswire)
Oct-25-24 11:32AM	Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update (GlobeNewswire)
08:30AM	Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 (GlobeNewswire)
Oct-23-24 08:30AM	SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial (GlobeNewswire) -5.19%
Oct-22-24 08:30AM	SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers (GlobeNewswire)
Oct-18-24 08:30AM	SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis (GlobeNewswire)
Oct-15-24 08:30AM	SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week (GlobeNewswire)
Oct-09-24 08:30AM	SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-08-24 08:30AM	SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities (GlobeNewswire)
Sep-25-24 08:30AM	SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial (GlobeNewswire) -6.26%
Sep-05-24 08:00AM	SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.14%
Sep-04-24 08:30AM	SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt (GlobeNewswire) +7.36%
Aug-23-24 05:45AM	SeaStar Medical Holding Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 6, 2024 to Discuss Your Rights - ICU (PR Newswire)
Aug-13-24 04:38PM	SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -16.51% -17.46%
Aug-08-24 12:38PM	SeaStar Medical Holding Corporation Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 6, 2024 to Discuss Your Rights ICU (GlobeNewswire)
Jul-26-24 09:00AM	Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE Therapy at Cincinnati Children's (GlobeNewswire) +11.53%
Jul-23-24 08:30AM	First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's FDA-Approved QUELIMMUNE Therapeutic Device (GlobeNewswire) +9.78%
Jul-17-24 09:00AM	Nuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's (GlobeNewswire)
Jul-16-24 08:30AM	CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical's Selective Cytopheretic Device Pivotal Trial (GlobeNewswire) +6.71%
Jul-12-24 08:30AM	SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner (GlobeNewswire) +12.27%
Jul-11-24 04:05PM	SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -5.08%
Jul-10-24 09:00AM	SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -37.92%
Jul-03-24 08:30AM	SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire) -10.53%
Jun-11-24 08:30AM	SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 08:30AM	SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company (GlobeNewswire) -23.25%
Jun-07-24 08:30AM	Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation (GlobeNewswire)
Jun-06-24 04:05PM	SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024 (GlobeNewswire) -39.41%
08:30AM	SeaStar Medical Announces 25-for-1 Reverse Stock Split (GlobeNewswire)
May-22-24 08:30AM	Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility (GlobeNewswire)
May-20-24 10:53AM	ICU Stock Earnings: SeaStar Medical Holding Misses EPS for Q1 2024 (InvestorPlace) +6.14%
May-14-24 04:05PM	SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -11.87%
Apr-30-24 08:30AM	SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure (GlobeNewswire) -6.61%
Apr-17-24 04:00PM	SeaStar Medical Reports 2023 Financial Results and Provides a Business Update (GlobeNewswire) -22.79%
Apr-16-24 11:52PM	ICU Stock Earnings: SeaStar Medical Holding Misses EPS for Q4 2023 (InvestorPlace) +7.20%
Apr-11-24 08:30AM	SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-02-24 11:26AM	LM Funding America, Inc. (NASDAQ:LMFA) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.95%
Mar-27-24 08:30AM	SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 (GlobeNewswire)
Mar-12-24 08:30AM	SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients (GlobeNewswire) +11.00%
Mar-11-24 04:05PM	SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 (GlobeNewswire) +11.64%
Feb-27-24 08:30AM	Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure (GlobeNewswire) -7.85%
Feb-22-24 07:58AM	Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune (GlobeNewswire) -23.45%
07:53AM	FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury (GlobeNewswire)
Feb-01-24 08:30AM	SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology (GlobeNewswire)
Jan-26-24 08:05AM	SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) -5.59%
Jan-11-24 04:05PM	SeaStar Medical Appoints David A. Green as Chief Financial Officer (GlobeNewswire) -8.41%
Jan-09-24 08:30AM	SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications (GlobeNewswire)
Dec-28-23 08:30AM	SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury (GlobeNewswire) -5.93%

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company was founded on June 6, 2007 and is headquartered in Denver, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Van Heel Kenneth	Director	Aug 26 '25	Buy	0.89	25,000	22,248	39,400	Aug 28 05:28 PM
Van Heel Kenneth	Director	Aug 27 '25	Buy	0.86	10,000	8,565	49,400	Aug 28 05:28 PM
Chung Kevin	Chief Medical Officer	Aug 22 '25	Buy	0.80	10,000	8,000	58,184	Aug 25 06:21 PM
Neuman John	Director	Jun 04 '25	Option Exercise	0.00	2,667	0	88,000	Jul 16 07:45 PM
Vincent Bernadette N	Director	Jun 04 '25	Option Exercise	0.00	2,667	0	8,000	Jul 16 07:45 PM
Van Heel Kenneth	Director	Jun 04 '25	Option Exercise	0.00	4,000	0	10,400	Jul 16 07:45 PM
Chung Kevin	Chief Medical Officer	Jul 01 '25	Option Exercise	0.00	5,000	0	48,184	Jul 03 04:33 PM
Schlorff Eric	Chief Executive Officer	Jul 01 '25	Option Exercise	0.00	21,667	0	98,517	Jul 03 04:33 PM
Baird Jennifer A	Director	Jun 04 '25	Option Exercise	0.00	2,667	0	18,000	Jul 02 07:32 PM
Baird Jennifer A	Director	Jun 30 '25	Buy	0.42	10,000	4,174	28,000	Jul 02 07:32 PM
Neuman John	Director	Jun 24 '25	Buy	0.36	40,000	14,396	80,000	Jun 27 06:00 AM
Baird Jennifer A	Director	May 20 '25	Buy	1.28	10,000	12,815	10,000	May 22 05:40 PM
Chung Kevin	Chief Medical Officer	May 20 '25	Buy	1.25	4,500	5,625	18,185	May 20 07:07 PM
Neuman John	Director	Dec 11 '24	Buy	2.04	10,000	20,405	40,000	Feb 27 03:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

ICU

SeaStar Medical Holding Corp

Upgrade your FINVIZ experience